Granules India Ltd's Q3FY25 Quarter Results
- 25 Jan 2025
Result Summary
- Granules India Ltd reported a 17.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 1.1%.
- Its expenses for the quarter were up by 17.7% QoQ and 0.5% YoY.
- The net profit increased 21.0% QoQ and decreased 6.4% YoY.
- The earnings per share (EPS) of Granules India Ltd stood at 4.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1143.37 | 969.87 | 1156.24 | 17.9% | -1.1% |
Total Expenses | 990.58 | 841.49 | 986.14 | 17.7% | 0.5% |
Profit Before Tax | 152.79 | 128.38 | 170.10 | 19.0% | -10.2% |
Tax | 35.19 | 31.15 | 44.44 | 13.0% | -20.8% |
Profit After Tax | 117.60 | 97.23 | 125.65 | 21.0% | -6.4% |
Earnings Per Share | 4.80 | 4.00 | 5.20 | 20.0% | -7.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Granules India Ltd is a prominent pharmaceutical company that specializes in the manufacture and distribution of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company operates within the pharmaceutical industry, delivering essential drugs and formulations to a global market. Although specific recent developments are not provided, companies in this sector typically engage in activities such as expanding their product portfolios, investing in research and development for new drug formulations, and enhancing manufacturing capabilities to meet regulatory standards. As an established entity in the pharmaceutical industry, Granules India Ltd is known for its commitment to quality and compliance with international regulatory requirements.
Revenue
In Q3FY25, Granules India Ltd reported a total income of ₹1,143.37 crores, reflecting a quarter-over-quarter (QoQ) increase of 17.9% from ₹969.87 crores in Q2FY25. However, when compared year-over-year (YoY) with Q3FY24, where the total income was ₹1,156.24 crores, there is a slight decline of 1.1%. The QoQ growth indicates an improvement in revenue generation over the recent quarter, while the YoY comparison highlights a marginal decrease from the previous year's figures for the same quarter. These figures suggest the company experienced substantial growth in revenue during the quarter, albeit with a slight decline when compared to the corresponding quarter of the previous fiscal year.
Profitability
Granules India Ltd's profitability metrics for Q3FY25 showed a profit before tax of ₹152.79 crores, marking a 19.0% increase from the ₹128.38 crores of the previous quarter, Q2FY25. There is, however, a 10.2% decrease when compared to the ₹170.10 crores from Q3FY24. The tax expense for Q3FY25 was ₹35.19 crores, reflecting an increase of 13.0% QoQ but a decrease of 20.8% YoY. Consequently, the profit after tax stood at ₹117.60 crores, up 21.0% QoQ from ₹97.23 crores, but down 6.4% YoY compared to ₹125.65 crores. Earnings per share (EPS) for Q3FY25 was ₹4.80, which increased by 20.0% from Q2FY25's EPS of ₹4.00, yet decreased by 7.7% from Q3FY24's EPS of ₹5.20. These figures reflect the company's profitability dynamics over the reported periods.
Operating Metrics
The operating metrics for Granules India Ltd, as derived from the financial data, indicate significant changes in both expenses and profit margins. Total expenses for Q3FY25 amounted to ₹990.58 crores, representing a 17.7% increase from Q2FY25's expenses of ₹841.49 crores and a slight increase of 0.5% from Q3FY24's ₹986.14 crores. This indicates that while expenses have risen significantly on a QoQ basis, they have remained relatively stable when compared YoY. These financial metrics provide a comprehensive view of the company's operational performance over the specified periods, offering insights into cost management and operational efficiency.
